Nidan, could it be that time was needed to prove out not just efficacy better than SOC in AD and Rett, where there was no drug available, but rather disease “midification” like we just saw with Rett Syndrome 5 mg trial? It my theory is correct we should see the next Adult Rett syndrome trial with disease “modification” and then the Pediatric and or Alzheimer trial.
Is this the “we will understand once we see…..” comment?
What does disease modification do, expand the label at approval? Accelerate prophylactic use?
Patiently waiting?